À¶Ý®ÊÓÆµ

Pharma Co. Brass Overhyped ALS Drug Efficacy, Suit Says

By Sydney Price ( March 22, 2024, 10:41 PM EDT) -- Executives and directors of neurodegenerative disease drugmaker Brainstorm Cell Therapeutics have been hit with a proposed class action alleging they damaged the company by overstating the effectiveness of its Lou Gehrig's disease drug even after the U.S. Food and Drug Administration rejected its license application....

À¶Ý®ÊÓÆµ is on it, so you are, too.

A À¶Ý®ÊÓÆµ subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A À¶Ý®ÊÓÆµ subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience À¶Ý®ÊÓÆµ today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login